Nectar Lifesciences Ltd. (NLL) is a knowledge driven organization which constitutes a vital part of fast growing Indian Pharmaceutical Industry. It has emerged as top ranked organization amongst midsized Pharmaceutical companies in India as per “Fortune Next 500” 2017 & is  among top 40 fore runners of the Bio-Pharmaceutical industry in Asia-Pacific Region as per “Bio-Spectrum Asia Pacific” 2016 besides being one of the top amongst Indian API manufacturers.

The company has transformed itself from being a small Domestic API player to one of the most integrated player in the Global Cephalosporins Industry within Anti Infective Therapeutic segment. It currently has a strong hold of API & Formulation business in many countries of the world with various State of Art manufacturing facilities spread across the States of Punjab and Himachal Pradesh with compliance to global standards of cGMP, Environment Health Safety (EHS) as well as pool of thousands of highly skilled, knowledgeable, competent qualified work force at all levels.

Business area of the company

The company has developed fully integrated sustainable production systems to manufacture high quality Cephalosporin intermediates, - Active Pharmaceuticals ingredients (APIs) and Finished Dosage Formulations (FDF or Formulations) to meet the diverse requirements of its customer base in India and over many countries worldwide.

Nectar Lifesciences Ltd.

MEDICO

Windlas Biotech Ltd.

Sakar Healthcare Ltd.

Lyka Labs Ltd.

Ind-Swift Laboratories Ltd.

Zota Health Care Ltd.

Albert David Ltd.

Lincoln Pharmaceuticals Ltd.

SMS Pharmaceuticals Ltd.

Brooks Laboratories Ltd.

Bliss GVS Pharma Ltd.

Venus Remedies Ltd.

Kilitch Drugs (India) Ltd.

Krebs Biochemicals & Industries Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	514 Cr		EPS	0.1		High	23.25
Stock P/E	179.7		Net Profit Margin	-5.0		Low	23.25

Open Price	22.95	Volume	26
Prev. Close	22.95

NECLIFE